Carotid atherosclerosis
Conditions
Interventions
control group:The control group was treated with atorvastatin calcium tablets (Qilu Pharmaceutical Group Co., Ltd., National Medicine Approval No. H20193144, dosage form 20mg/tablet), administered onc
experimental group:On the basis of the control group, Shuangqing Xiaoban Drink was used
Sponsors
Fujian University of Traditional Chinese Medicine Affiliated People's Hospital Affiliation of the Leader
Eligibility
Sex/Gender
All
Age
18 Years to 79 Years
Inclusion criteria
Inclusion criteria: 1) Meets the Western medical diagnosis of atherosclerosis and the traditional Chinese medical diagnosis of "Phlegm-dampness and Blood Stasis Syndrome. 2)Age range: 18 to 79 years; 3)Meets the diagnostic criteria for hyperlipidemia as specified in the "Chinese Guidelines for Lipid Management (2023 Edition) 4)The patient has complete basic information, can adhere to medication, and meets the conditions for follow-up; 5)The patient understood the study and signed the informed consent form.
Exclusion criteria
Exclusion criteria: 1) Abnormal liver function; 2) Allergic to the drug used in this study; 3) Acute cardiovascular and cerebrovascular disease; 4) Having significant trauma or after major surgery; 5) There are acute infectious diseases, autoimmune diseases, severe cardiopulmonary insufficiency; 6) Pregnant and lactating women.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Maximum soft plaque or mixed plaque length and thickness of carotid artery plaque; | — |
Secondary
| Measure | Time frame |
|---|---|
| Crouse rating;Ultrasound pathological classification of carotid artery plaques;Evaluation of therapeutic grade for carotid artery plaque;Traditional Chinese Medicine Syndrome Score;blood lipid profile;SAA;IL-1ß;IL-6;PI3K;Akt; | — |
Countries
China
Contacts
Public ContactWANG Ting
Fujian University of Traditional Chinese Medicine Affiliated People's Hospital
Outcome results
None listed